Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals

NCT07349212 is registered in ClinicalTrials.gov with Ukko Inc as lead sponsor.

NCT NCT07349212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07349212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals
Lead sponsor
Ukko Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 18, 2026
Completion date
November 1, 2027
Enrollment
40 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

peanut allergy, peanut-induced anaphylaxis